Currency In USD
| Previous Close | 9.13 |
| Open | 9.06 |
| Day High | 9.16 |
| Day Low | 7.87 |
| 52-Week High | 30.99 |
| 52-Week Low | 7.87 |
| Volume | 2.5M |
| Average Volume | 1.03M |
| Market Cap | 524.75M |
| PE | -2.56 |
| EPS | -3.1 |
| Moving Average 50 Days | 19.74 |
| Moving Average 200 Days | 21.21 |
| Change | -1.2 |
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Mar 04, 2026 1:30 PM GMT
BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded an
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Feb 26, 2026 9:01 PM GMT
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the closing of
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Feb 25, 2026 4:13 AM GMT
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the pricing of